Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Novo Nordisk shares declined on Monday after the company reported that its next-generation weight-loss drug, CagriSema, ...

A LOVED-UP mum’s bid to shine in her wedding dress went wrong after using a pharmacy-bought ‘fat jab’. Stephanie Hill decided ...

WHEN doctors told her she was overweight, former Big Brother star Narinder Kaur took a decision that could have claimed her ...

Vivani Medical, Inc. ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the successful administration of its ...

To sign up as a housing host, email [email protected] or fill out the Volunteer form on the Tour of the Gila website, checking the "host family" box. More encouragement is offered in the ...

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

Roche agreed to develop a weight-loss drug with Danish biotech Zealand Pharma, pressuring Novo Nordisk and Eli Lilly.